Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin

Endocrine Journal

Volumn 60, Issue 4, 2013, Pages 431-439

  Kusunoki, Yoshiki ^a   Katsuno, Tomoyuki ^a   Myojin, Makiko ^a   Miyakoshi, Kana ^a   Ikawa, Takashi ^a   Matsuo, Toshihiro ^a   Ochi, Fumihiro ^a   Tokuda, Masaru ^a   Murai, Kazuki ^a   Miuchi, Masayuki ^a   Hamaguchi, Tomoya ^a   Miyagawa, Jun ichiro ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

glucosidase inhibitor; Continuous glucose monitoring; Dipeptidyl peptidase 4 inhibitor; Incretin hormones

Indexed keywords

ACARBOSE; ALOGLIPTIN; BIGUANIDE DERIVATIVE; C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNCTION TEST; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; MALE; MEAL TOLERANCE TEST; MEAN AMPLITUDE OF GLYCEMIC EXCURSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS; POSTPRANDIAL STATE; PROTECTION; PROTEIN BLOOD LEVEL; WEIGHT CONTROL;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; OVERWEIGHT; PIPERIDINES; URACIL; WEIGHT GAIN;

EID: 84877001126     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, et al. (2006) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972.
2. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, et al. (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31: 1473-1478.
3. Del Prato S (2002) In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord 26: s9-17.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Coordinating Committee of the National Cholesterol Education Program, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44: 720-732.
5. Rosamond W, Flegal K, Friday G, Furie K, Go A, et al. (2007) Heart disease and stroke statistics -2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-171.
6. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, et al. (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57: 1349-1354.
7. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681-1687.
8. Hu Y, Liu W, Huang R, Zhang X (2010) Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. Atherosclerosis 210: 302-306.
9. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, et al. (2000) Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23: 1830-1834.
10. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidylpeptidase IV hydrolyzes gastric-inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine Methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
11. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
12. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K (2011) Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, doubleblind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 27: 1781-1792.
13. Bischoff H (1995) The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 18: 303-311.
14. Mori Y, Shiozaki M, Matsuura K, Tanaka T, Yokoyama J, et al. (2011) Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus. Diabetes Technol Ther 13: 467-470.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486-494.
16. http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes
17. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K (2011) Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 27: 21-29.
18. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, et al. (2012) Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 49: 225-230.
19. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57: 667-672.
20. Kishimoto M, Noda M (2011) A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovascular Diabetology 10: 115.
21. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W (1995) Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896.
22. Ranganath L, Norris F, Morgan L, Wright J, Marks V (1998) Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med 15: 120-124.
23. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like pep-tide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
24. Liu H, Hu Y, Simpson RW, Dear AE (2008) Glucagonlike peptide-1 attenuates tumour necrosis factor-α-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 196: 57-65.
25. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, et al. (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-1215.
26. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
27. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, et al. (2006) Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide. Diabetes 55: s86-91.